

05 February 2026

To National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 NSE Scrip Symbol: SaiLife	To BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai - 400001 BSE Scrip Code: 544306
---	--

Sub: Press release for the Un-audited Financial Results for the quarter and nine months ended on 31 December 2025.

Dear Sir/ Madam,

With reference to the above subject, we enclose herewith the Press release for the Un-audited financial results for the quarter and nine months ended on 31 December 2025.

We request you to take note of the same and oblige.

Thank you.

For **Sai Life Sciences Limited**

Runa Karan
Company Secretary & Compliance Officer
Membership No.: A13721

Encl: As above

Sai Life Sciences Limited (CIN: L24110TG1999PLC030970)

Corporate office

L4-01 & 02, SLN Terminus, Survey
#133, Gachibowli Miyapur Road,
Gachibowli, Hyderabad – 500032,
Telangana, India.

Registered office

Plot No. DS-7, IKP Knowledge Park, Turkapally
(V), Shameerpet Mandal, Medchal-Malkajgiri
(Dist), Hyderabad -500078, Telangana, India.

Contact us

T: +91 40 6815 6000,
F: +91 40 6815 6199
E: info@sailife.com
W: www.sailife.com

Sai Life Sciences Limited delivers robust performance in 9MFY26

Revenue up by 43%; EBITDA up by 79%; Net Profit up by 199%

Hyderabad, February 05, 2026: Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India's fastest growing Contract Research, Development and Manufacturing Organizations (CRDMO) announced its financial results for the third quarter and nine months ended December 2025.

Financial Performance:

Particulars (₹ crores)	Q3FY26	Q3FY25	YoY%	9MFY26	9MFY25	YoY%
Revenue from Operations	556	440	27%	1,590	1,115	43%
EBITDA	191	124	54%	472	264	79%
EBITDA Margin%	34%	28%		30%	24%	
PBT	134	72	87%	327	109	200%
PAT	100	54	86%	245	82	199%
PAT Margin%	18%	12%		15%	7%	

Q3FY26 Highlights

- Revenue from Operations was ₹556 Cr for Q3FY26 compared to ₹440 Cr in Q3FY25, **an increase of 27%** driven by strong growth both in CRO and CDMO services.
- EBITDA stood at ₹191 Cr for Q3FY26 compared to ₹124 Cr in Q3FY25, **an increase of 54%**.
- PAT stood at ₹100 Cr for Q3FY26 compared to ₹54 Cr in Q3FY25, **an increase of 86%**.

9MFY26 Highlights

- Revenue from Operations was ₹1,590 Cr for 9MFY26 compared to ₹1,115 Cr in 9MFY25, **an increase of 43%**.
- EBITDA stood at ₹472 Cr for 9MFY26 compared to ₹264 Cr in 9MFY25, **an increase of 79%**.
- PAT stood at ₹245 Cr for 9MFY26 compared to ₹82 Cr in 9MFY25, **an increase of 199%**.

Business Highlights

- AI & Digital Platforms:**
 - Applied AI driven retrosynthetic analysis to ML generated compounds, accelerating route design and improving synthetic efficiency.
 - Successfully delivered a full library of AI designed macrocyclic peptides, demonstrating AI's role in complex modality generation.
- Technology Adoption & Infrastructure Scale-Up:**
 - Created a centralized group for Photochemistry and Electrochemistry, enabling broader adoption of modern reaction technologies.
 - Strengthened Flow capabilities across Discovery & CMC; successfully scaled late-phase photo flow bromination; next GMP plug-flow step commencing.
- Automation & High-Throughput Experimentation:**
 - Implemented automated permeability measurement platform in Discovery, High Throughput Experimentation (HTE) module in India, and continuous counter current LLE towards plant scale equipment.
- Capex**
 - Invested ₹405 Cr as on date in capital expenditure, against a plan of ₹700 Cr for FY26
- Quality and Compliance Excellence**
 - During the quarter, successfully completed 8 customer audits across manufacturing and R&D units, with zero data integrity deviations and zero critical observations
- Sustainability**
 - Released 6th Sustainability Report 2024–25, outlining progress against ESG priorities.

- Achieved My Green Lab (MGL) Green-level certification for two PR&D laboratories and two Medicinal Chemistry laboratories, with over 98% compliance—the highest standard under the MGL framework.
- Published a joint sustainability case study with Bayer on The Climate Drive, highlighting the increased adoption of a hybrid solar–wind captive power model at the Bidar manufacturing site under a long-term power purchase agreement (PPA).

Commenting on the performance during the quarter, Mr. Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences Limited, said, “Q3 FY26 marked continued progress in building Sai Life Sciences into a science-led, globally relevant CRDMO. During the quarter, we strengthened our technology platforms through greater adoption of digital, AI-enabled and modern chemistry approaches, enhancing our ability to support increasingly complex programs for global innovator clients.

In parallel, we continued to build organizational depth by adding experienced scientific and leadership talent, ensuring our teams scale in step with our expanding capabilities. Our capacity expansion plans remain firmly on track, with manufacturing scale-up and process development infrastructure progressing in line with our long-term roadmap. These investments are being guided by the evolving scientific contours of next-generation medicines and the changing needs of our customers.

Looking ahead, we remain confident in sustaining our growth momentum in the coming year. With disciplined execution and a clear strategic direction, Sai Life Sciences is well positioned to support the next phase of innovation while creating long-term value for all stakeholders.”

Mr. Siva Chittor, Chief Financial Officer, Sai Life Sciences Limited added, “We have delivered a robust growth in Q3 FY26 which outperformed the broader CRDMO industry trend, with improved operating performance, driven by disciplined execution and healthy momentum across our businesses.

For the quarter, total revenue stood at ₹556 Cr, representing a 27% year-on-year increase, supported by sustained demand and healthy volume growth across key service lines. EBITDA grew by 54% year-on-year to ₹191 Cr, with margins expanding by 605 bps to 34%, supported by improved capacity utilization, operational efficiencies, and ongoing cost optimization initiatives.

As of date, we have invested ₹405 Cr in capital expenditure, aligned with our long-term strategy to strengthen capabilities and expand capacity. This investment remains in line with our guided FY26 capex plan and reinforces our commitment to building scalable, future-ready infrastructure.

We continue to focus on prudent capital allocation and margin discipline while investing selectively in areas that enhance our differentiated value proposition. With strengthened capabilities, a solid order pipeline, and a more resilient operating foundation, we are well positioned for another year of strong and profitable growth, creating enduring value for our stakeholders.”

Earnings Call:

Sai Life Sciences will conduct earnings call at 4.00 PM (IST) on 6 February 2026 to discuss the financial and business performance of the quarter. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time.

Date	February 6, 2026
Time	04:00 PM – 5:00 PM (IST)
Dial-in Number	+91 22 6280 1107, +91 22 7115 8008
International Toll Free	USA: 18667462133 UK: 08081011573 Singapore: 8001012045 Hong Kong: 800964448
Pre-Registration Facility	Click here

About Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE)

Sai Life Sciences is one of India's fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO) that partners with innovator pharmaceutical and biotech companies to accelerate the discovery, development, and commercialization of new medicines. Headquartered in Hyderabad, India, with a strong global presence, the company offers integrated solutions spanning medicinal chemistry, process development, clinical and commercial manufacturing, and advanced technology platforms. Sai Life Sciences is committed to delivering high-quality, cost-effective, and scalable solutions while upholding the highest standards of safety, compliance, and integrity. With a focus on innovation and operational excellence, the company continues to strengthen its capabilities to support emerging therapeutic modalities and meet the evolving needs of the life sciences industry.

For more information, please visit www.sailife.com

For further details, please feel free to contact: Investorrelation@sailife.com

Disclaimer:

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects on the Company. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, change in laws and regulations that apply to pharmaceuticals, increasing competition in and changes in political conditions in India. Neither Sai Life, nor our directors, assume any obligation to update any forward-looking statement contained in this release. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.